SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

PF-08046040 is under clinical development by Pfizer and currently in Phase I for Relapsed Acute Myeloid Leukemia.

Eunice S. Wang, MD, discusses a retrospective study of 105 patients diagnosed with secondary acute myeloid leukemia.

Interesting trends were observed in the subgroup analyses of the phase 3 uproleselan study in relapsed or refractory acute ...

The holidays can be especially tough for cancer patients, but two best friends are making the best of it by supporting each ...

Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO) is pleased to announce the opening of ...

This year’s most-viewed articles and videos on myelodysplastic syndromes (MDS) explored patient quality of life, risk factors ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, announces a summary of the feedback received from the US Food and Drug Administr ...

JMP Securities lowered the firm’s price target on Vor Bio (VOR) to $6 from $12 and keeps an Outperform rating on the shares. Following a ...

The "ER" star plays Ephron in "Left on Tenth," a Broadway adaptation of the writer's memoir of surviving cancer and getting a ...

EDINBURGH, Scotland, Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic ...